Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Not pending/lapsed |
21 | DE file number | DAKZ | 60 2012 067 211.0 |
96 | EP file number | EAKZ | 17 19 1721.4 |
97 | EP publication number | EPN | 3275892 |
54 | Designation/title | TI | RSV-F-PRÄFUSIONSANTIGENE |
51 | IPC main class | ICM (ICMV) | C07K 14/135 (2006.01) |
22 | DE application date | DAT | May 14, 2012 |
96 | EP application date | EAT | May 14, 2012 |
43 | Date of first publication | OT | Jan 31, 2018 |
| Date of publication of grant | PET | Jan 8, 2020 |
71/73 | Applicant/owner | INH | Glaxosmithkline Biologicals S.A., Rixensart, BE |
72 | Inventor | IN | SWANSON, Kurt, Emeryville, CA 94662-8097, US; CARFI, Andrea, Emeryville, CA 94662-8097, US |
74 | Representative | VTR | VOSSIUS & PARTNER Patentanwälte Rechtsanwälte mbB, 81675 München, DE |
| Address for service | | VOSSIUS & PARTNER Patentanwälte Rechtsanwälte mbB, 81675 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201161486005 P May 13, 2011
|
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003275892A2 Searchable text:
EP000003275892A2 Original document:
EP000003275892B1 Searchable text:
EP000003275892B1 |
43 | Date of first publication | EVT | Jan 31, 2018 |
| Date of the first transfer into DPMAregister | EREGT | Jan 31, 2018 |
| Date of the (most recent) update in DPMAregister | REGT | Jul 20, 2023 (Show all update days)(Hide all update days)- Jul 20, 2023; Jun 29, 2023; Jun 15, 2023; Mar 3, 2022; Jan 16, 2022; Apr 23, 2020; Jan 23, 2020; Dec 19, 2019; Aug 23, 2019; Aug 1, 2019
- Historical data not available for this/these date(s)
- Jan 31, 2018
- Date of the first transfer into DPMAregister
|